Taizhou Biotech, charging towards top free players
Update time:
2026-11-17 08:07
Reads:
The self exemption track is becoming one of the most active sub tracks in this wave of going global, with billion dollar level transactions appearing intensively on self exemption channels such as TL1A, IL-23, TSLP, etc.
On November 5th, Quanxin Biotechnology announced an authorized partnership with Caldera Therapeutics for preclinical dual antibodies targeting TL1A/IL-17, with a down payment of $30 million, a maximum clinical, regulatory, and commercial milestone of $750 million, and tiered sales royalties, with a potential total consideration of $780 million.
The buyer is not unfamiliar. Caldera is a NewCo company newly established in April last year, based on the overseas asset QX030N of Quanxin Biotechnology. With this core asset, Caldera has completed a second round of financing totaling $112.5 million and plans to advance its listing on the New York Stock Exchange through a reverse merger. Only 18 months later, Caldera turned around and asked Quanxin for a "second purchase".
Pull the camera away, the signal will be clearer.
In the past two years, Quanxin Biotechnology has completed four overseas authorizations with Caldera, Roche, and Windward Bio, covering three completely different types of buyers: NewCo, Global MNC, and Overseas Biotech, with a cumulative potential total amount (calculated based on cash payment) exceeding $3.1 billion.
The density and diversity of BD transactions are unparalleled in the industry, especially among small and medium-sized biotech companies.
When overseas transactions are no longer scarce, why did this biotech company, which grew up in Taizhou China Medical City, break through the encirclement and develop its own pace of going global and internationalization? How does it transform repeated transactions into a replicable and redeemable system capability?
For this reason, Tong Xieyi once again interviewed the "landing driver" behind this series of transactions - Wu Shenglong, Chief Business Officer and Deputy General Manager of Quanxin Biotechnology. According to him, just like last year, the company still does not have a strictly large BD team. "From beginning to end, there was only me and two capable assistants, along with the full support of the boss and the entire company," he said.
In his opinion, the underlying logic that supports this high-density and high-quality overseas achievement is not only the high efficiency of the Chinese team, the company's differentiated technology platform, and excellent asset quality, but also the company culture of steady, down-to-earth, and professional cooperation.
Taking this as a clue, in this interview, Wu Shenglong deeply analyzed how a small and medium-sized biotech company, with its top-down determination, keen sense of opportunity, efficient resource allocation, and sincere communication, obtained continuous bets from overseas buyers, providing another unique model for China's new drug development path abroad.

Wu Shenglong
Chief Business Officer and Deputy General Manager of Quanxin Biotechnology
1、How was a 'repurchase transaction' born
When it comes to the newly landed deal with Caldera, Wu Shenglong said that the pace of progress in this deal is very fast: "From the actual start of negotiations to signing, it took about a month, less than two months
But speed does not mean haste. He revealed that this cooperation between the two sides has actually been "brewing for more than half a year" - Caldera expressed interest in similar products six months ago, and the two sides have been discussing what kind of pipeline to build, "which is equivalent to communication and consensus between the two sides, and also somewhat similar to customization".
Focusing on the trading target, this is a preclinical dual antibody that simultaneously targets TL1A and IL-17: the project targets both pathways simultaneously and is expected to exert synergistic effects, providing differentiated treatment options for related immune-mediated diseases.
As for why Caldera "restocked", the logic is not complicated.
Caldera was originally a NewCo company established based on the assets of Quanxin Biotechnology. In April 2025, the two parties reached the first NewCo transaction, and Caldera obtained the exclusive global license for Quanxin Biotechnology's long-acting self exempt dual antibody QX030N (Caldera internal code: CLD-423). Over the past year of cooperation, the two parties have established a good level of trust and understanding.
QX030N targets IL-23p19 and TL1A for the treatment of IBD and other immune-mediated diseases. For a long time, Caldera had only one single pipeline. Whether for the consideration of enriching pipelines or the need for capital market listing and financing, it requires a richer asset portfolio to diversify investment risks.
With the finalization of the new transaction, Caldera's target combination on the TL1A pathway has been further enriched - in addition to IL-23p19 × TL1A, IL-17 × TL1A has been added. Caldera also pointed out in the press release that the addition of the IL-17 × TL1A project expands the company's strategy of developing multi-target biologics for the treatment of inflammatory pathways.
If the second move was the result of building trust between both parties, then Caldera's own growth curve exceeded Quanxin's initial expectations.
On the day of the official announcement of the transaction, Caldera also released new data on the single and multiple dose cohorts of QX030N's Phase Ia healthy volunteer trial: the lowest half-life exceeded 40 days, and free TL1A was inhibited to below the lower limit of quantification within two hours, supporting the launch of Phase II clinical trials for QX030N in early 2027 for ulcerative colitis (UC) and Crohn's disease (CD).
With the steady progress of QX030N clinical trials, Quanxin Biotechnology has also achieved milestones and sustained revenue as a result. Last December, when QX030N obtained ethical approval for Phase I clinical trials from the Australian Human Research Ethics Committee (HREC), Caldera paid a milestone payment of $5 million to Quanxin.
The pace of capital has also opened up the "double speed" mode.
Caldera was established in early 2025 and immediately completed a $75 million Series A financing, followed by a $37.5 million Series A1 financing; In July 2026, Caldera announced a full stock merger with Synlogic and simultaneously raised approximately $278 million in private equity funding. The merger is expected to be completed in early 2027 and listed on the New York Stock Exchange under the code "CALD".
The company formed a closed loop in less than two years from its establishment to listing, which greatly exceeded our expectations, "Wu Shenglong sighed." At the same time, it is unimaginable for a single product to accumulate $400 million in financing within two years in the Chinese capital market
In his opinion, being able to run at such a speed is not only due to the strong capital operation and clinical development capabilities of Caldera's management team, but also to the solid strength of the assets themselves. During the implementation of Phase I clinical trials, our safety, pharmaceutical, and PK characteristics all met our initial expectations. "
02. BD methodology of a small and medium-sized biotech company
Extending the timeline, this repurchase transaction is just the latest piece of puzzle added to Quanxin Biotechnology's overseas expansion.
In addition to Roche's QX031N and Windward Bio's QX027N, Quanxin Bio has disclosed the completion of four overseas transactions in the past two years, with a cumulative potential total amount exceeding $3.1 billion. It should be noted that the down payment between Windward Bio and Caldera also includes equity consideration. If the equity value is included, the overall transaction size will further increase on this basis.

Counting the commonalities of the four overseas transactions, all of which are self-developed long-term self exempt dual antibodies, this also reflects the international market's unanimous optimism towards long-term self exempt dual antibodies.
Wu Shenglong also stated that the self exemption track has been quite popular in recent years because it is a large and very important market in itself, and there are significant unmet needs. As long as the products are differentiated, there is a great opportunity to go global and internationalize.
From the perspective of buyer differences, different companies have different demands and priorities. MNC may place more emphasis on pipeline development quality, while investors and NewCo may be more risk averse, with different priorities. However, the common demand is that the asset quality is strong. ”
Of course, signing the contract is just the beginning. What really gives the company confidence is the speed at which these pipelines are being developed overseas. "So far, all the projects we signed last year have achieved phase one development milestones.
In Wu Shenglong's view, the pipeline is being pushed quickly due to solid preclinical research and solid data, as well as solid teamwork and tacit cooperation between the two teams. As the project enters the milestone stage, the trust and tacit understanding of existing customers continue to improve, and the potential for BD in the future greatly increases.
In addition, this BD and the ability to cash in are also reflected in the financial statements.
According to the 2025 annual report, Quanxin Biotechnology achieved a total revenue of 807 million yuan, a year-on-year increase of 408.2%; Among them, the external authorization income was 723 million yuan, mainly from the two transactions of QX030N and QX031N; The profit for the year was 307 million yuan, with an adjusted profit of 356 million yuan, achieving annual profit for the first time since its listing.
Entering 2026, the momentum continues. In the first half of the year, the operating revenue reached 424 million yuan, a year-on-year increase of 105.37%; The authorization agreement revenue is 379 million yuan, mainly from the down payment and non cash consideration of QX027N's overseas authorization, as well as milestone payments of QX008N and QX031N; The net profit attributable to the parent company was 203 million yuan, turning losses into profits year-on-year.
When asked why he was able to achieve such results, Wu Shenglong followed the viewpoint he gave in an interview last year: "It's still a matter of timing, location, and people - it's just that the location is getting more and more favorable now, and people are getting more and more compatible
Gradually breaking down this sentence, there are five interlocking abilities: anchoring direction with strategic strength, seizing opportunities with a sense of timing, amplifying leverage with resource organization, fulfilling commitments with execution efficiency, and building trust through continuous communication.
In the face of the increasingly competitive and homogeneous market, he emphasized the subjective initiative of BD in seizing opportunities. "When customers extend olive branches, they should be able to respond immediately and quickly drive the company's functions. At the same time, external resources should still be used, which can improve efficiency and save time.
In addition, customer communication is also crucial, whether it is in the contract stage or later execution stage. Throughout the entire process, they feel that you are very professional and efficient, and they are still willing to work with you later.
03. Tides and Boundaries: Regulatory Variables and Trend Analysis
Currently, the background of innovative drugs going global and BD is undergoing drastic changes. On the one hand, in the first three quarters of 2026, the total amount of foreign authorizations for innovative drugs exceeded 130 billion US dollars, and China has become the world's largest BD trading country; On the other hand, BD transactions are becoming increasingly normalized, but market reactions to BD are also diverging.
At the same time, the regulatory environment has become an unavoidable variable in the narrative of going global - the US Treasury's COINS bill proposes to expand restrictions on investment in biopharmaceuticals, while the Chinese Ministry of Commerce and Ministry of Science and Technology have also included five types of technologies such as CGT and small nucleic acid in their export control catalog.
Faced with such a change, Wu Shenglong's judgment is quite calm. He bluntly stated that BD is primarily a matter of life and death, and going global is an inevitable choice. "The payment situation and market capacity in the Chinese market cannot accommodate so many innovative pharmaceutical companies. Without internationalization and going global, there is only one dead end.
When it comes to the ups and downs of stock prices brought by BD, his attitude is also pragmatic: "BD belongs to non recurring gains and losses, and is not necessarily related to stock prices. But BD is a matter of life and death for a company, and it can transform one-time income into sustainable income. “
Despite regulatory changes, Wu Shenglong remains confident in the prospects of China's innovative drugs going global. In his view, there are no substantial barriers set by regulators for conventional license outs, whether from China or the United States. What requires approval and sensitivity is another type of transaction: the transfer of ownership of the entire technology platform or mergers and acquisitions at the company level.
In other words, what is truly affected is not 'authorizing the pipeline', but 'selling the company or platform as a whole'.
Based on the above judgment, he believes that the BD craze for innovative drugs in China will continue.
The efficiency and cost advantages of Chinese assets in differentiated innovation on mature targets objectively exist. The efficiency and cost structure of Western companies determine that it is difficult for them to compete with us in this dimension. As long as China's efficiency advantages, cost advantages, and differentiation capabilities remain, the demand for going global is there
Amidst this trend, when it comes to Quanxin Biotechnology's future BD plans, the key word given by Wu Shenglong is "diversification". Quanxin has currently tried two paths, License out and NewCo, and will consider deeper models such as Co Co (joint development), asset packaging authorization, and joint ventures in the future.
Of course, these models have much higher requirements for teams, operations, and internationalization than pure authorization, but the level of participation is also higher. A truly ambitious company must cultivate its internationalization capabilities through this gradual cooperation approach.
However, he also emphasized that Quanxin would not "carve a boat and seek a sword", limiting himself to a certain mode. We will choose the most suitable model based on different products, development stages, and partner demands. He added.
- Write at the end -
From the trial of the first NewCo transaction to the multi line flowering of NewCo, MNC, and overseas Biotech, Quanxin Biotechnology has forged a breakthrough path for China's small and medium-sized biotech industry with four overseas transactions and a potential total of over 3.1 billion US dollars on the global map of self exemption track.
This road is not waiting. It relies on strategic determination to anchor direction, the ability to seize opportunities, the rapid execution of the entire company, and professional, efficient, and sincere communication to turn contract terms into clinical progress, milestones into the trust of partners, and trust into "secondary procurement" repurchase.
When License out and NewCo are no longer scarce, what is truly scarce is the ability to turn transactions into cash and cash into compound interest. Quanxin Biotechnology has proven with four transactions that small and medium-sized biotech companies do not need to be greedy for big things, but must be down-to-earth and have a global perspective; There is no need to carve boats and seek swords, nor to blindly believe in a certain pattern, but one must dare to think and act.
Internally running a commercial closed loop, relying on the continuous increase in volume of already marketed monoclonal antibody products; Through high-density BD cooperation and diversified overseas routes, this enterprise, which grew up in Taizhou China Medical City, is accelerating its entry into the top players of domestic self exemption.
Previous page
Related News